The global Dipeptide Peptidase 4 (DPP-4) Inhibitors market size is predicted to grow from US$ 9642 million in 2025 to US$ 11110 million in 2031; it is expected to grow at a CAGR of 2.4% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Dipeptide Peptidase 4 (DPP-4) Inhibitors are a class of oral diabetes drugs that work by blocking the action of DPP-4, an enzyme which destroys a group of gastrointestinal hormones called incretins. Incretins help stimulate the production of insulin when it is needed (e.g. after eating) and reduce the production of glucagon by the liver when it is not needed (e.g. during digestion). They also slow down digestion and decrease appetite. So by protecting incretins from damage, DPP-4 inhibitors help regulate blood glucose levels.

Januvia (Sitagliptin), Galvus (Vildagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin) are the major DPP-4 drugs in the market.

Infinity Market Research newest research report, the Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Forecast looks at past sales and reviews total world Dipeptide Peptidase 4 (DPP-4) Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected Dipeptide Peptidase 4 (DPP-4) Inhibitors sales for 2025 through 2031. With Dipeptide Peptidase 4 (DPP-4) Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dipeptide Peptidase 4 (DPP-4) Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global Dipeptide Peptidase 4 (DPP-4) Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dipeptide Peptidase 4 (DPP-4) Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Dipeptide Peptidase 4 (DPP-4) Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dipeptide Peptidase 4 (DPP-4) Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dipeptide Peptidase 4 (DPP-4) Inhibitors.

This report presents a comprehensive overview, market shares, and growth opportunities of Dipeptide Peptidase 4 (DPP-4) Inhibitors market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Sitagliptin
    Saxagliptin
    Linagliptin
    Alogliptin
    Vildagliptin

Segmentation by Application:

    Hospitals
    Clinics

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Merck
    Eli Lilly
    AstraZenica
    Boehringer Ingelheim
    Takeda Pharmaceutical Company
    BMS

Key Questions Addressed in this Report

What is the 10-year outlook for the global Dipeptide Peptidase 4 (DPP-4) Inhibitors market?
What factors are driving Dipeptide Peptidase 4 (DPP-4) Inhibitors market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Dipeptide Peptidase 4 (DPP-4) Inhibitors market opportunities vary by end market size?
How does Dipeptide Peptidase 4 (DPP-4) Inhibitors break out by Type, by Application?